Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44]
1 Drug Development Department, Gustave Roussy, University of Paris Sud, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: christophe.massard@gustaveroussy.fr.
2 BC Cancer Agency, Vancouver, Canada.
3 University Hospital 12 de Octubre, CIBER-ONC, Madrid, Spain.
4 Institute of Cancer Research, London, UK.
5 Institut Paoli-Calmettes, Marseille, France.
6 St. Augustinus Hospital, Antwerp, Belgium.
7 Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Universitécatholique de Louvain, Brussels, Belgium.
8 Cedars-Sinai Medical Center, Los Angeles, CA, USA.
9 Medical Oncology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain.
10 Novartis Pharma S.A.S, Rueil-Malmaison, France.
11 Novartis Pharma AG, Basel, Switzerland.
12 Novartis Healthcare Pvt. Ltd., Hyderabad, India.
13 Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, France.